Rare mutations in the ADAM10 gene make a genetic case for the amyloid cascade as a cause of late onset Alzheimer's disease.
What’s better for future treatment of Parkinson’s: patient-derived or banked iPSCs? In comparison, patient’s own come out on top.
Antibodies against extracellular tau block seeding, diminish brain pathology, and may improve cognition in a mouse model.
Proposed preclinical stages for Alzheimer’s disease predict well who is most likely to progress to Alzheimer’s dementia.
It's not just for neurodevelopment anymore. Death receptor 6—known for pruning axons—also trims unused connections in adulthood, hinting at a function in Alzheimer's.
The NIH announced $45 million in new funding to support trials in preclinical Alzheimer’s populations, as well as efforts to identify new therapeutic targets.
New research proposes a neuroimmune receptor as the latest Aβ binding partner.
The first report on PBB3, the latest tau ligand for brain imaging under development, suggests it binds all types of tau aggregate.
A deletion in chromosome 22 points to new genetic risk factors for Parkinson's disease.
FUS, a protein tied to neurodegeneration, normally mends DNA breaks, according to a paper in Nature Neuroscience.
A new study supports the idea that non-motor symptoms of Parkinson's disease may aid earlier diagnosis.
Older people improved memory and attention after playing a challenging video game, supporting the idea that multitasking could have benefits for cognition.
New imaging data suggests degeneration of the fornix could help identify seniors on the verge of cognitive decline.
Amyloid fibrils seeded by Alzheimer’s brain extracts indicate that Aβ forms specific strains in different individuals.
New research connects extracellular Aβ to intracellular kinases that mediate its toxicity.